Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

Video

Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.

Related Videos
Scott Morgan, MD, MSc, FRCPC, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Todd M. Morgan, MD, answers a question during a Zoom video interview
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Matthew Loria answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with doctor | Image Credit: © DragonImages - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.